Final hours! Save up to 55% OFF InvestingProCLAIM SALE

Vaccine Stocks Benefit From Covid-19 Variant Concerns

Published 26/11/2021, 16:44
DJI
-
PFE
-
NVAX
-
INO
-
MRNA
-
BNTX
-
VIR
-

By Sam Boughedda

Investing.com — Covid-19 related vaccine stocks have made gains Friday after concerns were raised about a new coronavirus variant in South Africa that is said to have several mutations.

With concerns being raised about the variant's potential ability to evade current vaccines, stocks such as Pfizer Inc (NYSE:PFE), BioNTech SE (NASDAQ:BNTX), Moderna Inc (NASDAQ:MRNA), Inovio Pharmaceuticals Inc (NASDAQ:INO), Novavax Inc (NASDAQ:NVAX), Vir Biotechnology Inc (NASDAQ:VIR), and others have surged. 

Pfizer shares rose 6%. Moderna rose 23%. Inovio rose more than 8%, while Novavax shares rose more than 9%. Vir rose 16%. Meanwhile, the Dow Jones Industrial Average lost more than 2%, or 850 points, in morning trading.

According to Reuters, BioNTech said it expects further data on the new variant within the next two weeks and that if necessary, it would be able to redesign the vaccine within 6 weeks and deliver batches within 100 days.

In certain European countries, a reintroduction of lockdown restrictions has already started, with cases rising once again. In addition, while some commentators have described the variant as the "most concerning" so far, it is important to note that not much is known about it just yet, with scientists still working to understand its implications.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.